Spero Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 46
- Market Cap
- $74.5M
- Introduction
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. M...
Spero Therapeutics Gets Investor Suit Over FDA Approval Tossed
Spero Therapeutics Inc. investors cannot proceed with a class action over optimistic statements about a clinical trial and treatment's FDA approval, ruled by the US District Court for the Eastern District of New York. The court found insufficient intent for securities fraud allegations after the FDA's negative feedback on an anti-bacterial pill in 2022.
Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary
FDA accepts GSK's NDA for gepotidacin, a novel oral antibiotic for uUTIs, with a PDUFA action date of 26 March 2025. Gepotidacin, supported by positive EAGLE-2 and EAGLE-3 trials, could be the first new class of oral antibiotic for uUTIs in over 20 years.
Antibiotic Resistance Research Report 2024: 6 Key Large Opportunities in this Space and ...
The 'Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type' report outlines market players addressing antimicrobial resistance, including drug manufacturers, biotech companies, and regulatory bodies. It highlights the role of diagnostics in combating AMR and identifies 6 key market opportunities. The report provides five-year market forecasts and profiles over 100 biotech companies.
© Copyright 2024. All Rights Reserved by MedPath